HCW Biologics Inc. received written notice from Nasdaq that the company regained compliance with the Bid Price Rule (Listing Rule 5550(a)(2)) per the terms of a Panel decision letter. The company will be subject to a Mandatory Panel Monitor until June 17, 2027, and may face delisting if it fails to satisfy remaining terms by September 22, 2026. HCW Biologics Inc. is a biotechnology company focused on the development and commercialization of biologics.
